Jiang Bing-Hua, Liu Ling-Zhi
Mary Babb Randolph Cancer Center and Department of Microbiology, Immunology and Cell Biology, West Virginia University, Morgantown, West Virginia 26506, USA.
Adv Cancer Res. 2009;102:19-65. doi: 10.1016/S0065-230X(09)02002-8.
Phosphatidylinositol 3-kinase (PI3K) and phosphatase and tensin homolog deleted on chromosome 10 (PTEN) signaling pathway play an important role in multiple cellular functions such as cell metabolism, proliferation, cell-cycle progression, and survival. PI3K is activated by growth factors and angiogenesis inducers such as vascular endothelial growth factor (VEGF) and angiopoietins. The amplification and mutations of PI3K and the loss of the tumor suppressor PTEN are common in various kinds of human solid tumors. The genetic alterations of upstream and downstream of PI3K signaling molecules such as receptor tyrosine kinases and AKT, respectively, are also frequently altered in human cancer. PI3K signaling regulates tumor growth and angiogenesis by activating AKT and other targets, and by inducing HIF-1 and VEGF expression. Angiogenesis is required for tumor growth and metastasis. In this review, we highlight the recent studies on the roles and mechanisms of PI3K and PTEN in regulating tumorigenesis and angiogenesis, and the roles of the downstream targets of PI3K for transmitting the signals. We also discuss the crosstalk of these signaling molecules and cellular events during tumor growth, metastasis, and tumor angiogenesis. Finally, we summarize the potential applications of PI3K, AKT, and mTOR inhibitors and their outcome in clinical trials for cancer treatment.
磷脂酰肌醇3激酶(PI3K)和10号染色体缺失的磷酸酶及张力蛋白同源物(PTEN)信号通路在细胞代谢、增殖、细胞周期进程及存活等多种细胞功能中发挥着重要作用。PI3K可被生长因子以及血管内皮生长因子(VEGF)和血管生成素等血管生成诱导剂激活。PI3K的扩增和突变以及肿瘤抑制因子PTEN的缺失在各类人类实体瘤中很常见。PI3K信号分子上游(如受体酪氨酸激酶)和下游(如AKT)的基因改变在人类癌症中也经常发生。PI3K信号通过激活AKT及其他靶点并诱导HIF-1和VEGF表达来调节肿瘤生长和血管生成。血管生成是肿瘤生长和转移所必需的。在本综述中,我们重点介绍了关于PI3K和PTEN在调节肿瘤发生和血管生成中的作用及机制,以及PI3K下游靶点在信号传导中的作用的最新研究。我们还讨论了这些信号分子在肿瘤生长、转移和肿瘤血管生成过程中的相互作用及细胞事件。最后,我们总结了PI3K、AKT和mTOR抑制剂的潜在应用及其在癌症治疗临床试验中的结果。